Overview

Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics

Status:
Completed

Trial end date:
2012-03-20

Target enrollment:

Participant gender:

Summary

This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected infections that are caused by a specific group of bacteria (called Gram-positive bacteria)or perioperative subjects that are receiving prophylactic antibiotics .

Phase:

Phase 1

Details

Lead Sponsor:

Cubist Pharmaceuticals LLC

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular
Daptomycin